Zealand Pharma Develops ZP2929 For Type 2 Diabetes
ZP2929, to significantly decrease body weight and reduce the risk of Diabetes-related complications
Zealand Pharma has reported that it is developing a new treatment, ZP2929, for Type 2 Diabetes. ZP2929 has the potential to significantly decrease body weight and reduce the risk of Diabetes-related complications. The drug is now moving into pre-clinical development.
ZP2929 is a dual Glucagon-GLP-1 agonist, a peptide drug which interacts with two receptor systems that play a role in metabolism and Type 2 Diabetes.
David Solomon, CEO of Zealand Pharma, said: We have been through a long and exciting research period. The result is a new dual Glucagon-GLP-1 agonist that both controls the blood glucose levels and reduces weight in obese diabetic models.
We feel confident that our new dual Glucagon-GLP-1 agonist ZP2929, with its properties, will lead to a greater weight loss than its competitors.
Related Insight
Suppliers Directory
TAPI - A Leading Global Supplier of Active Pharmaceutical Ingredients
With more than 70 years of experience and over $1.9 billion in annual sales, TAPI is a leading global supplier of active pharmaceutical ingredients. TAPI (Teva Active Pharmaceutical lngredients) is a stand alone business unit of Teva Pharmaceutical Industries limited.
Suppliers
Fuld & Company – Competitive Intelligence and Strategic Gaming
Fuld & Company, the global leader in competitive intelligence, delivers customised research and analysis on markets, competitors, suppliers and customers.
Suppliers
EnviroChemie - Reliable Water and Wastewater Treatment
As partners to the industry, we develop and implement customised solutions by concentrating all our efforts in meeting the individual requirements of our customers.
Suppliers
FANUC Robotics - Flexible Automation
FANUC Corporation is a Japanese manufacturer specialising in robotics and CNC.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Smart HPLC Solutions for Large Molecules
Published by Tosoh Bioscience
White Papers
The Many Faces of Water Vapor
Published by Vaisala
White Papers
Learn More About DSM
Published by DSM
White Papers
Right Place, Right Time
Published by Centrical Global Limited
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.